Pharmacologic inhibitors of IκB kinase suppress growth and migration of mammary carcinosarcoma cellsin vitroand prevent osteolytic bone metastasisin vivo
- 1 August 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 8 (8) , 2339-2347
- https://doi.org/10.1158/1535-7163.mct-09-0133
Abstract
The NF-κB signaling pathway is known to play an important role in the regulation of osteoclastic bone resorption and cancer cell growth. Previous studies have shown that genetic inactivation of IκB kinase (IKK), a key component of NF-κB signaling, inhibits osteoclastogenesis, but the effects of pharmacologic IKK inhibitors on osteolytic bone metastasis are unknown. Here, we studied the effects of the IKK inhibitors celastrol, BMS-345541, parthenolide, and wedelolactone on the proliferation and migration of W256 cells in vitro and osteolytic bone destruction in vivo. All compounds tested inhibited the growth and induced apoptosis of W256 cells as evidenced by caspase-3 activation and nuclear morphology. Celastrol, BMS-345541, and parthenolide abolished IL1β and tumor necrosis factor α–induced IκB phosphorylation and prevented nuclear translocation of NF-κB and DNA binding. Celastrol and parthenolide but not BMS-345541 prevented the activation of both IKKα and IKKβ, and celastrol inhibited IKKα/β activation by preventing the phosphorylation of TAK1, a key receptor–associated factor upstream of IKK. Celastrol and parthenolide markedly reduced the mRNA expression of matrix metalloproteinase 9 and urinary plasminogen activator, and inhibited W256 migration. Administration of celastrol or parthenolide at a dose of 1 mg/kg/day suppressed trabecular bone loss and reduced the number and size of osteolytic bone lesions following W256 injection in rats. Histomorphometric analysis showed that both compounds decreased osteoclast number and inhibited bone resorption. In conclusion, pharmacologic inhibitors of IKK are effective in preventing osteolytic bone metastasis in this model and might represent a promising class of agents to the prevention and treatment of metastatic bone disease associated with breast cancer. [Mol Cancer Ther 2009;8(8):2339–47]Keywords
All Related Versions
This publication has 40 references indexed in Scilit:
- Interactions between microenvironment and cancer cells in two animal models of bone metastasisBritish Journal of Cancer, 2008
- An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cellsBlood, 2007
- Targeting NF‐κB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growthBritish Journal of Haematology, 2007
- Parthenolide, a Natural Inhibitor of Nuclear Factor-κB, Inhibits Lung Colonization of Murine Osteosarcoma CellsClinical Cancer Research, 2007
- Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-κB–regulated gene products and TAK1-mediated NF-κB activationBlood, 2006
- Skeletal Complications of Breast Cancer TherapiesClinical Cancer Research, 2006
- Rat Models of Bone MetastasesClinical & Experimental Metastasis, 2005
- Effects of IKK inhibitor PS1145 on NF-κB function, proliferation, apoptosis and invasion activity in prostate carcinoma cellsOncogene, 2005
- Bone Invasion by Walker 256 Carcinoma, Line A in Young and Adult Rats: Effects of EtidronateOncology, 1990
- Protective Effects of a Prophylactic Treatment with the Bisphosphonate 3-Amino-1 -Hydroxypropane-1,1 -Bisphosphonic Acid on the Development of Tumor Osteopathies in the Rat: Experimental Studies with the Walker Carcinosarcoma 256Oncology, 1988